These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 21557459)

  • 1. Transplant-associated thrombotic microangiopathy in pediatric patients treated with sirolimus and tacrolimus.
    Rosenthal J; Pawlowska A; Bolotin E; Cervantes C; Maroongroge S; Thomas SH; Forman SJ
    Pediatr Blood Cancer; 2011 Jul; 57(1):142-6. PubMed ID: 21557459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus.
    Labrador J; López-Corral L; López-Godino O; Vázquez L; Cabrero-Calvo M; Pérez-López R; Díez-Campelo M; Sánchez-Guijo F; Pérez-López E; Guerrero C; Alberca I; Del Cañizo MC; Pérez-Simón JA; González-Porras JR; Caballero D
    Bone Marrow Transplant; 2014 May; 49(5):684-90. PubMed ID: 24566710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.
    Shayani S; Palmer J; Stiller T; Liu X; Thomas SH; Khuu T; Parker PM; Khaled SK; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2013 Feb; 19(2):298-304. PubMed ID: 23078784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
    Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
    Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402).
    Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS
    Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrapatient variability in concentration/dose ratio of tacrolimus predicts transplant-associated thrombotic microangiopathy.
    Sagou K; Fukushima N; Ukai S; Goto M; Ozeki K; Kohno A
    Int J Hematol; 2021 Jan; 113(1):63-72. PubMed ID: 32876853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurologic Complications of the Central Nervous System after Allogeneic Stem Cell Transplantation: The Role of Transplantation-Associated Thrombotic Microangiopathy as a Potential Underreported Cause.
    Sala E; Neagoie AM; Lewerenz J; Saadati M; Benner A; Gantner A; Wais V; Döhner H; Bunjes D
    Transplant Cell Ther; 2024 Jun; 30(6):586.e1-586.e11. PubMed ID: 38508452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention.
    Khimani F; Kim J; Chen L; Dean E; Rizk V; Betts B; Nishihori T; Locke F; Mishra A; Perez L; Ayala E; Kharfan-Dabaja M; Nieder M; Fernandez H; Anasetti C; Pidala J
    Bone Marrow Transplant; 2017 Jul; 52(7):1003-1009. PubMed ID: 28368376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation.
    Mirza AS; Tandon A; Jenneman D; Cao S; Brimer T; Kumar A; Kidd M; Khimani F; Faramand R; Mishra A; Liu H; Nishihori T; Perez L; Lazaryan A; Bejanyan N; Nieder M; Anasetti C; Pidala J; Elmariah H
    Transplant Cell Ther; 2022 Apr; 28(4):185.e1-185.e7. PubMed ID: 35017119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transplantation-Associated Thrombotic Microangiopathy in Patients Treated With Sirolimus and Cyclosporine as Salvage Therapy for Graft-Versus-Host Disease.
    García-Martín P; Alarcón-Payer C; López-Fernández E; Moratalla L; Romero A; Sainz J; Ríos R; Jurado M
    Ann Pharmacother; 2015 Sep; 49(9):986-94. PubMed ID: 26160968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT.
    Cutler C; Logan B; Nakamura R; Johnston L; Choi S; Porter D; Hogan WJ; Pasquini M; MacMillan ML; Hsu JW; Waller EK; Grupp S; McCarthy P; Wu J; Hu ZH; Carter SL; Horowitz MM; Antin JH
    Blood; 2014 Aug; 124(8):1372-7. PubMed ID: 24982504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
    Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II pilot study of tacrolimus/sirolimus GVHD prophylaxis for sibling donor hematopoietic stem cell transplantation using 3 conditioning regimens.
    Rodriguez R; Nakamura R; Palmer JM; Parker P; Shayani S; Nademanee A; Snyder D; Pullarkat V; Kogut N; Rosenthal J; Smith E; Karanes C; O'Donnell M; Krishnan AY; Senitzer D; Forman SJ
    Blood; 2010 Feb; 115(5):1098-105. PubMed ID: 19965688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Yamane T; Hasegawa T; Nakamae M; Terada Y; Hagihara K; Ohta K; Hino M
    Am J Hematol; 2006 Jul; 81(7):525-31. PubMed ID: 16755559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation.
    Kharfan-Dabaja MA; Parody R; Perkins J; Lopez-Godino O; Lopez-Corral L; Vazquez L; Caballero D; Falantes J; Shapiro J; Ortí G; Barba P; Valcárcel D; Esquirol A; Martino R; Piñana JL; Solano C; Tsalatsanis A; Pidala J; Anasetti C; Perez-Simón JA
    Bone Marrow Transplant; 2017 Mar; 52(3):438-444. PubMed ID: 27819684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplant-associated thrombotic microangiopathy: Incidence, prognostic factors, morbidity, and mortality in allogeneic hematopoietic cell transplantation.
    Gavriilaki E; Sakellari I; Batsis I; Mallouri D; Bousiou Z; Vardi A; Yannaki E; Constantinou V; Tsompanakou A; Vadikoliou C; Kaloyannidis P; Bamihas G; Anagnostopoulos A
    Clin Transplant; 2018 Sep; 32(9):e13371. PubMed ID: 30080283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting.
    Kharfan-Dabaja MA; Pidala J; Anasetti C
    Blood; 2010 May; 115(21):4316-7; author reply 4317. PubMed ID: 20508174
    [No Abstract]   [Full Text] [Related]  

  • 20. The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
    Pulsipher MA; Langholz B; Wall DA; Schultz KR; Bunin N; Carroll WL; Raetz E; Gardner S; Gastier-Foster JM; Howrie D; Goyal RK; Douglas JG; Borowitz M; Barnes Y; Teachey DT; Taylor C; Grupp SA
    Blood; 2014 Mar; 123(13):2017-25. PubMed ID: 24497539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.